For the Inventor, By the Inventor

Enter assignee name

Bioprojet

Calculating rank

USPTO Granted Patents = 24

% Expired Patents = 12.5

CIPO Patents = 5

EPO Patents = 17

Forward Citations = 53

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Jeanne-Marie Lecomte (22 out of 56 patents)

Jean-Charles Schwartz (22 out of 62 patents)

Xavier Ligneau (14 out of 20 patents)

4. Marc Capet (12 out of 41 patents)

5. Philippe Robert (12 out of 13 patents)

6. Nicolas Levoin (10 out of 11 patents)

7. Isabelle Berrebi-Bertrand (9 out of 11 patents)

8. Thierry Calmels (7 out of 8 patents)

9. Olivier Labeeuw (6 out of 8 patents)

10. Stéphane Krief (5 out of 7 patents)

11. Xavier Billot (5 out of 6 patents)

12. Denis Danvy (5 out of 21 patents)

13. David Perrin (3 out of 7 patents)

14. Rajamannar Thennati (2 out of 47 patents)

15. Laurent Landais (2 out of 2 patents)

24 patents: Sort by Forward Citations

1. 12134608 - Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands (2024-11-05),

2. 12059416 - Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof (2024-08-13),

3. 11306069 - Benzimidazole derivatives as dual histamine H1 and histamine H4 receptor ligands (2022-04-19),

4. 11229632 - Combinations of a H3 antagonist and a noradrenaline reuptake inhibitor, and the therapeutical uses thereof (2022-01-25),

5. 11078183 - Tetrahydrate of H3 ligand, its process of preparation and pharmaceutical compositions comprising the same (2021-08-03),

6. 10952987 - Combination of adrenalin with an antidepressant for use in the treatment of shocks (2021-03-23),

7. 9439853 - Form of administration of enkephalinase inhibitor (2016-09-13),

8. 9266867 - Piperidinyl monocarboxylic acids as S1P1 receptor agonists (2016-02-23),

9. 9255101 - 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands (2016-02-09),

10. 9242959 - (Aza)benzhydryl ether derivatives, their process of preparation and their use as H4-receptor ligands for therapeutical applications (2016-01-26),

11. 9029357 - Benzazole derivatives as histamine H4 receptor ligands (2015-05-12),

12. 8809539 - Dicarboxylic acid derivatives as S1P1 receptor agonists (2014-08-19),

13. 8802678 - [object Object] (2014-08-12),

14. 8486947 - [object Object] (2013-07-16),

15. 8354430 - Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine (2013-01-15),

Company Overview

Bioprojet is a biopharmaceutical company based in Paris, France, specializing in the development of innovative therapies for central nervous system disorders. The organization focuses on research and development in the fields of neuropharmacology and drug delivery systems, aiming to address unmet medical needs through advanced scientific approaches. With a commitment to improving patient outcomes, Bioprojet collaborates with various stakeholders in the healthcare sector to bring its pioneering solutions to market.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

24 Patents

#209 in Paris

#878 in France

#26,686 in the World

Bioprojet

Forward Citations = 53

49 inventors:

Jeanne-Marie Lecomte (22 out of 56 patents)

Jean-Charles Schwartz (22 out of 62 patents)

Xavier Ligneau (14 out of 20 patents)

4. Marc Capet (12 out of 41 patents)

5. Philippe Robert (12 out of 13 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Bioprojet. Retrieved from https://idiyas.com/company/bioprojet

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…